FDA Clears Next-Generation AI Software for Portable Brain MRI
The Optive AI software, the tenth software release for the Swoop portable MRI system, reportedly offers enhanced clarity and anatomical detail for ultra-low-field MRI of the brain.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Optive AI software, which may significantly elevate the quality of ultra-low-field brain MRI scans.
The tenth software release for the Swoop portable MRI system, the Optive AI software utilizes advanced algorithms to bolster noise cancellation, image reconstruction and post-processing, according to Hyperfine, the developer of the Swoop MRI platform.
The newly FDA-cleared Optive AI software (see MRI scan on the right) enhances the clarity and anatomical details of ultra-low-field MRI scans obtained with the Swoop portable MRI system, according to Hyperfine, the manufacturer of the Swoop system. (Images courtesy of Hyperfine.)
Hyperfine noted that use of the Optive AI software allows for sharper clarity and anatomical detail across all sequences obtained with ultra-low-field brain MRI.
“The advanced AI algorithms integrated into our new software platform dramatically elevate image quality at ultra-low field strength, enabling more confident diagnoses at the point of care,” noted Rafael O’Halloran, the vice president of technology at Hyperfine.
The company said the Optive AI software will be available in the third quarter of 2025.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
